activistletters
Galloway Capital Presses Chicago Rivet (CVR) on Market Mispricing, Calls for Enhanced Investor Outreach
Summary
Galloway Capital Partners, which owns about 6.45% of Chicago Rivet & Machine Co., argues that the company is
activistletters
Ampco Pittsburgh (AP) Draws Activist Support From Galloway Capital Partners as Letter Highlights Valuation Gap and M&A Options
Summary
Galloway Capital Partners disclosed that it has built a 5.19% stake in Ampco Pittsburgh over the past 18
activistletters
STAAR Surgical (STAA) Faces Intensifying Pushback as Broadwood Partners Opposes Sale and Presses for Independence
Summary
Broadwood strongly opposed STAAR Surgical’s proposed sale to Alcon, arguing the deal materially undervalues the company and reflects
activistletters
OraSure Technologies (OSUR) Faces Proxy Fight as Altai Capital Seeks Board Seats Over Governance and Strategic Failures
Summary
Altai Capital disclosed a 5.2% stake in OraSure and sharply criticized the Board for clinging to a failed
activistletters
Global Crossing Airlines (JET) Draws Activist Interest as Galloway Capital Pushes M&A or Going-Private Options
Summary
Galloway Capital disclosed that it has increased its stake in Global Crossing Airlines to 6.24%, reiterated its view
activistletters
Yunqi Capital Challenges STAAR Surgical (STAA) Board, Rejects Alcon Merger Over Timing, Process, and Valuation
Summary
In a December 10, 2025 letter, Yunqi Capital reiterated its opposition to STAAR Surgical’s proposed sale to Alcon,
activistletters
Broadwood Partners Targets STAAR Surgical (STAA) Over Flawed Sale Process and Undervalued Alcon Offer
Summary
Broadwood Partners’ supplemental presentation argues that Alcon’s proposed acquisition of STAAR Surgical should be rejected because it is
activistletters
Lifeway Foods (LWAY): Smolyansky Shareholders Push Director Replacements and Challenge Governance Amid Danone Fallout
Summary
The presentation argues that Lifeway’s largest shareholders, Edward and Ludmila Smolyansky (26% owners), are pushing for board change
activistletters
Scully Royalty (SRL): Activist Shareholder MILFAM LLC Accuses Board of Blocking Valid Director Nominees and Manipulating AGM Process
Summary
MILFAM LLC, a 13% shareholder of Scully Royalty, rejects the company’s claim that its director nominations were invalid,
activistletters
Alaunos Therapeutics (TCRT): Activist Shareholder Group Seeks Board Seat for Gerald W. Bruce Amid Strategic Concerns
Summary
The shareholder group holding 8.61% of Alaunos Therapeutics urges the board to accept their formal nomination of Gerald
activistletters
BILL Holdings (BILL): Activist Barington Capital Urges Board to Review Strategy and Reduce Costs as Growth and Monetization Slow
Summary
Barington Capital, a BILL shareholder, argues that despite the company’s strong positioning in B2B financial automation and solid
activistletters
First Industrial (FR): Land & Buildings Presses Board on Mispriced Portfolio, Urges Steps to Unlock 30% NAV Upside
Summary
Land & Buildings argues that First Industrial (FR) is a high-quality industrial warehouse REIT trading at an unjustified discount
activistletters
Neuphoria Therapeutics (NEUP): Lynx1 Challenges Board’s Strategic Review and Capital Decisions, Refiles Offer and Nominates Two Independent Directors
Summary
Lynx1, the largest shareholder of Neuphoria, argues that the company’s severe value destruction—driven by failed trial design,
activistletters
Noodles & Company (NASDAQ: NDLS) Urged by Galloway Capital to Pursue Asset Sales and Deleveraging Strategy
Summary
The letter argues that Noodles & Company is undervalued and urges the Board to sell roughly 200 company-owned restaurants
activistletters
UniFirst (UNF): Engine Capital Challenges Board Entrenchment and Calls for Sale Process Amid Years of Value Destruction
Summary
Engine Capital’s presentation argues that UniFirst’s value destruction stems from entrenched governance, the Croatti family’s control,
activistletters
Engine Capital Pressures UniFirst (UNF) Board on Dual-Class Control, Value Destruction, and Rejection of Takeover Interest
Summary
Engine Capital tells UniFirst’s independent directors that investors and analysts overwhelmingly agree the company is on the wrong
activistletters
Lynx1 Capital Challenges Neuphoria Therapeutics (NEUP) Board Over Entrenchment, Strategic Review Flaws, and Value Destruction
Summary
Lynx1’s presentation argues that Neuphoria’s leadership mishandled the failed AFFIRM-1 Phase 3 trial, lacked transparency, and pursued
activistletters
Carronade Capital Escalates Campaign at Cannae Holdings (CNNE), Citing NAV Declines, Related-Party Deals, and Failed Oversight
Summary
Carronade’s presentation argues that Cannae’s long-standing governance failures—director entrenchment, conflicted related-party deals, and poor oversight—have
